Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Paclitaxel

8 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCGI15146

    08/05/2016

    A Multicenter, Randomized, Open-label Study in Patients with Esophageal Cancer Refractory or Intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Treatment

    VICCBRE1552

    02/02/2016

    A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

    Treatment

    VICCGYN1518

    08/26/2015

    A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations

    Treatment

    VICCPHI1436

    08/18/2014

    A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

    Treatment

    VICCBRE1320

    08/16/2013

    A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

    Treatment

    ECOGTHO4508-M

    12/07/2010

    Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy


    Print this page for your doctor